Abstract
A novel liver function test was developed using formation kinetics of the metabolite monoethylglycinexylidide (MEGX) after i.v. bolus injection of lidocain (1 mg/ kg). Formation of MEGX is based upon a cyt. P-450 dependent N-deethylation step. The MEGX test was performed (1, 2) using a fluorescence polarisation immunoassay as described perviously. 38 patients aged 0.5-24 y have been tested so far. They suffered fran biliary atresia (BA) (n=6), chronic hepatitis (LC) (n=11) and hepatic based metabolic disease (HMD) (n=12). Children with normal liver function 1-4 years after liver transplantation (LTX) completed this series (n=9). In addition, 11 normal subjects (NORM) (mean age 23 y) were tested. Results are given in ug/1 (15 min values).
Patients with MEGX senm concentrations <11 ug/l did not survive 4 weeks unless they were transplanted. In cirrhotic patients MEGX senm concentrations between 12 and 50 ug/l indicated severe hepatic impairment, whereas concentraticns >90 ug/1 were not associated with clinically significant hepatic dysfunction. Adverse effects of the test were not observed so far. According to our preliminary findings this test gives valuable prognostic information in pediatric liver disease.
Ref. 1) Oellerich, M. et al., J. Clin. Chan. Clin. Biochem. 25, 845, 1967;
2) Burdelski, M. et al., Transpl. Proc. 19, 3838, 1987.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Burdelski, M., Oellerich, M. 85 Evaluation of a novel liver function test in pediatric liver disease. Pediatr Res 24, 419 (1988). https://doi.org/10.1203/00006450-198809000-00108
Issue date:
DOI: https://doi.org/10.1203/00006450-198809000-00108
